BILLS-116hr3573ih.pdf

23:48 Jul 09 JUNE 27, 2019 5 years biannual 1ST SESSION H. R. 3573 1800 2019 biennially

the ‘‘Cerebral Cavernous the ‘‘CCM–CARE Act

Track, Breakthrough Therapy Designation

States CCM the Southeastern United States Georgia Florida Louisiana Kansas the United States of America Alabama South Carolina Kentucky Texas Oklahoma New Mexico Colorado California the United States

IH Southwest

Hispanic Jewish American Spanish Ashkenazi

CCM NIH SEC the National Institutes of Health State U.S.C. Senate the Public Health Service tional Institutes of Health the National Heart, Lung the Commissioner of Food and Drugs the National Institutes of 17 Health the Committee on Health NATIONAL INSTITUTES OF HEALTH Education the Department of Health the Federal Food, Drug CCM FUNDING FOR BIOTECH Project the National Center for Advancing tional Sciences the National Center for Advancing Translational BIOMARKER FOOD AND DRUG ADMINISTRATION House of Representatives Labor Clinical Research Centers Committee the National Institute of Neurological House of Representa- the Department of 20 Health and Human Services the National Institute of Neurological Disorders the Centers for Disease Control Orphan Drug Designation THE HOUSE OF REPRESENTATIVES TECHNICAL ASSISTANCE.—In the Committee on Energy and Commerce Congress Trial Readiness Research Project Blood Institute Energy and Commerce the Commissioner of Food and 10 Drugs Drug Administration bral Cavernous Malformations Research Consortium Health and Human Services Accelerated Review TRANSLATIONAL

SORTIUM TORRES LUJA´N HAALAND

clinical research institutes research education common nih grants cooperative patients hispanic brain blood currently diagnosis trained expansion